Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia 5Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 3Anemia, Refractory, with Excess of Blasts 3Leukemia, Promyelocytic, Acute 2Leukemia, Myeloid, Accelerated Phase 2Blast Crisis 2Neutropenia 1Leukemia, Myeloid, Acute 1Anemia, Refractory 1

Interventions

Cyclophosphamide 27fludarabine phosphate 21Cyclosporine 19Mycophenolic Acid 16Busulfan 16Cord Blood Stem Cell Transplantation 15Antilymphocyte Serum 14Whole-Body Irradiation 13Radiotherapy 13Peripheral Blood Stem Cell Transplantation 11Methylprednisolone 9Filgrastim 7Methotrexate 6Melphalan 6Tacrolimus 5fludarabine 4Thiotepa 4Etoposide 4Cytarabine 4sargramostim 3Granulocyte Colony-Stimulating Factor 3Cyclosporins 3Azacitidine 3Decitabine 2Arsenic Trioxide 24-phenylbutyric acid 2vatalanib 1poly ICLC 1paricalcitol 1lintuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Anemia, Refractory × lintuzumab × Clear all
NCT00997243 2017-05-10

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
7 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡